% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Kaaks:300364,
author = {R. Kaaks$^*$ and V. Cooley$^*$ and T. Mukama$^*$ and L. R.
Teras and A. V. Patel and G. Masala and M. Crous-Bou and H.
R. Harris and H. Langseth and H.-M. Surcel and N. Wentzensen
and K. Terry and N. Sasamoto and S. Tworoger and R.
Turzanski-Fortner$^*$},
title = {{A} {P}rospective {S}tudy {C}onsortium for the {D}iscovery
and {V}alidation of {E}arly {D}etection {M}arkers for
{O}varian {C}ancer ('{PREDICT}') - {B}aseline findings for
{CA}125.},
journal = {Clinical cancer research},
volume = {31},
number = {12},
issn = {1078-0432},
address = {Philadelphia, Pa. [u.a.]},
publisher = {AACR},
reportid = {DKFZ-2025-00798},
pages = {2441-2453},
year = {2025},
note = {#EA:C020#LA:C020# / 2025 Jun 13;31(12):2441-2453},
abstract = {Epithelial ovarian cancer (EOC) is a lethal malignancy.
CA125, the 'best' available marker for detecting EOC, has
insufficient sensitivity and specificity for earlier-stage
disease and is not a meaningful screening tool, motivating
the search for further biomarkers. Cancer biomarker
discovery is enhanced by 'omics' technologies. Discovery
studies for EOC biomarkers should be conducted in
pre-diagnosis blood samples from prospective cohorts to
maximize likelihood of identifying markers that can detect
disease before usual diagnosis and in earlier disease stage,
while reducing methodologic biases.Individual cohorts with
pre-diagnosis blood samples have insufficient sample size
for such studies. thus, we established 'PREDICT'
('Prospective Early Detection Consortium for Ovarian
Cancer')-a collaboration of nine prospective studies-to
assemble a sufficient number of EOC cases with blood samples
collected ≤18 months before diagnosis plus controls. The
457 cases and 1,687 controls have circulating CA125 measured
using a clinical assay.The discrimination capacity for
single CA125 measurements in samples collected <6 months
prior to diagnosis was high (area under the curve (AUC),
PREDICT overall=0.92; range across cohorts of non-pregnant
individuals=0.89-0.98), and declined with extended time
between blood collection and diagnosis. Between-cohort
variability in CA125 levels and predictive performance was
observed.Ongoing investigations in PREDICT are evaluating
the early detection potential of tumor-associated
autoantibodies and microRNAs, using CA125 as a benchmark.
PREDICT is a well-characterized resource for identifying and
validating detection markers for EOC that may then be used
in multi-modal screening, as a complement to CA125 and
combined with imaging.},
cin = {C020},
ddc = {610},
cid = {I:(DE-He78)C020-20160331},
pnm = {313 - Krebsrisikofaktoren und Prävention (POF4-313)},
pid = {G:(DE-HGF)POF4-313},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:40227208},
doi = {10.1158/1078-0432.CCR-24-1845},
url = {https://inrepo02.dkfz.de/record/300364},
}